+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.

Age: 50Years - 85YearsAll GendersPhase 2
80 locations
M

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Master Protocol study focusing on the safety and tolerability of multiple amyloid-targeting drugs in both healthy adults and individuals diagnosed with Alzheimers disease AD. This study aims to evaluate if these drugs can remove amyloid plaque, clumps of protein in the brain linked to AD. Participants will enroll in one of two substudies, either A1D-MC-AT01 or the upcoming A1D-MC-AT02, to assess these treatments. The study involves administering the drug LY4405094 or a placebo either intravenously IV or subcutaneously SC to healthy volunteers and AD participants. Participants with AD will also undergo amyloid positron emission tomography PET scans using Florbetapir F18 or Florbetaben F18 injected intravenously to help monitor amyloid plaque in the brain. The study uses a randomized, double-blind design and includes several substudies depending on participant health status. Participants will be closely monitored throughout the study period, which lasts up to 160 days from baseline. Evaluations include medical exams, electrocardiograms ECGs, cognitive assessments such as the Mini-Mental State Exam MMSE, and brain imaging with PET scans and magnetic resonance imaging MRI. Study partners will assist participants with Alzheimers disease by providing support and consent. Researchers will track the number of participants assigned to each substudy and assess safety and tolerability during the trial.

Age: 18Years - 85YearsAll GendersPhase 1
18 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
R

Actively Recruiting

Researchers are evaluating the effect of a transdermal formulation called SFG-02 on Bladder Voiding Efficiency BVE in adults with Underactive Bladder UAB. This Phase 2a proof-of-concept study aims to assess both the impact on bladder function and the safety of the treatment compared to a placebo. Participants have symptoms like urinary hesitancy, straining to void, or weak urinary stream and meet specific bladder function criteria. Participants will undergo a 4-week placebo run-in period followed by 8 weeks of daily application of either the SFG-02 patch or a placebo patch. Each patch is worn for a full day, and participants will apply a new patch every day for a total treatment duration of 12 weeks. The study uses a randomized, double-blind design to compare the active drug to placebo. During the study, participants will visit the clinic every 2 to 4 weeks for checkups and tests. They will keep diaries to record bladder symptoms and the timing of patch changes. Researchers will monitor changes in Bladder Voiding Efficiency from baseline to the end of treatment as the primary outcome. Safety will also be assessed through laboratory tests and heart monitoring, with the entire participation lasting approximately 12 weeks.

Age: 18Years +All GendersPhase 2
16 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug ozanimod RPC1063 in treating pediatric participants aged 2 to 17 years who have moderate to severe active ulcerative colitis UC. These participants have not responded adequately to standard treatments. The study is a combined Phase 23, randomized, double-blind trial aimed at achieving and maintaining clinical remission in this population. Participants will receive oral ozanimod at different dose levels as part of the study. The treatment involves specified doses given on specific days. The study includes two experimental groups receiving either a high or low dose of ozanimod. The trial will assess outcomes over various time points, including up to 70 weeks for pharmacokinetics and safety monitoring, and follow-up for adverse events up to 6 years. During the study, participants will be closely monitored through clinical assessments, endoscopic evaluations, and laboratory tests. Researchers will measure remission rates, clinical responses, symptomatic remission, corticosteroid-free remission, endoscopic improvement, and lymphocyte counts. Safety will be tracked by documenting adverse events and serious adverse events throughout the study and follow-up period. The primary outcome is the proportion of participants achieving clinical remission at Week 52.

Age: 2Years - 17YearsAll GendersPhase 2Phase 3
91 locations
E

Actively Recruiting

This research aims to evaluate whether participants who have previously taken donanemab experience clinical benefits when receiving annual doses. The study focuses on individuals with Alzheimer disease, dementia, and amyloid plaque conditions, investigating the effects of continued treatment over a period of up to 2.5 years with six visits. The trial is sponsored by Eli Lilly and Company and is conducted as a randomized, double-blind, phase 3 clinical trial. Participants are assigned to receive either donanemab or a placebo, both administered intravenously. The study follows a parallel design where each participant receives one of the two treatments. The annual dosing schedule spans up to 2.5 years, with visits planned throughout this period to monitor participants. This includes assessments of cognitive function, brain amyloid plaque levels via PET scans, plasma biomarkers, and drug concentration measurements. During the study, participants will undergo evaluations including the Clinical Dementia Rating - Sum of Boxes CDR-SB, Cognitive Function Index CFI, Florbetapir F 18 PET scans, and plasma phosphorylated tau measurements. Pharmacokinetics of donanemab will be assessed at baseline, week 52, and week 104. The study involves six visits over the entire duration, with safety and clinical benefit monitored carefully. Participation lasts up to 2.5 years, allowing comprehensive observation of treatment effects.

Age: 55Years +All GendersPhase 3
62 locations
E

Actively Recruiting

Researchers are evaluating whether donanemab, given as an intravenous infusion, can slow down the worsening of thinking, learning, memory, attention, and daily functioning in people with early cognitive decline and features of dementia with Lewy bodies. This phase 2 study focuses on participants aged 55 to 85 who show evidence of both amyloid and alpha-synuclein brain pathology. The trial is randomized and placebo-controlled to compare donanemab against a placebo. Participants will receive either donanemab or a placebo via IV infusion during the study. The treatment period lasts up to 52 weeks, during which various clinical and biomarker assessments will be conducted. The study includes monitoring for drug concentrations and immune responses. Both groups receive infusions under a quadruple-masked design to ensure unbiased results. Throughout the one and a half year participation, participants will be regularly evaluated using cognitive and functional tests like the Clinical Dementia Rating scale, Alzheimers Disease Rating Scales, and brain imaging to measure amyloid plaque levels. Safety assessments include monitoring for adverse effects and antibody development. Study partners familiar with the participants daily abilities provide additional information. The study aims to observe changes from baseline over the 52-week treatment period.

Age: 55Years - 85YearsAll GendersPhase 2
72 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and tolerability of LY4006895, a study drug, in both healthy volunteers and participants with early symptomatic Alzheimers Disease AD. The study includes two parts Part A involves single-ascending doses in healthy participants, and Part B involves multiple-ascending doses in participants with early AD. The study aims to better understand how LY4006895 behaves in the body, including how much enters the bloodstream and how long it takes to be eliminated. Participants in Part A will receive single intravenous IV doses of LY4006895 or a placebo, while those in Part B will receive multiple IV doses of LY4006895 or placebo. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo. The entire study lasts approximately 29 weeks for Part A and 61 weeks for Part B, including screening periods. During the study, participants will have blood tests to measure drug levels and monitor safety. Researchers will track any treatment-related side effects, serious adverse events, and study discontinuations. Participants with early AD must have study partners who will assist with visits and provide consent. The primary outcome is the number of participants experiencing adverse events up to 61 weeks. The study includes regular assessments to ensure participant safety and gather pharmacokinetic data throughout the trial.

Age: 45Years - 85YearsAll GendersPhase 1
13 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating LY4405094, a drug being studied for safety and how it enters the bloodstream, in both healthy participants and those with Alzheimers Disease. The study aims to understand how much and how quickly LY4405094 reaches the bloodstream and brain fluid, while also assessing levels of a specific Alzheimers-related protein in the brain. This is a Phase 1 trial that includes a placebo comparison and uses both intravenous IV and subcutaneous SC administration methods. Participants are assigned randomly to receive either LY4405094 or a placebo, given by IV or SC in healthy volunteers and by IV in participants with Alzheimers Disease. The study includes a single-ascending dose group and a multiple-ascending dose group. Those with Alzheimers will also undergo amyloid positron emission tomography PET scans using Florbetapir F 18 or Florbetaben F 18 to assess amyloid plaque levels. Study stays include a 4-day clinical research unit visit for healthy volunteers and a 3-day stay for Alzheimers participants. During the study, researchers monitor participants for serious adverse events related to the study drug over up to 25 weeks. They also measure drug concentration levels in blood and cerebrospinal fluid, and track amyloid plaque changes using PET scans. Participants will undergo clinical stays, blood tests, scans, and safety monitoring throughout the study period, which lasts up to 13 weeks for healthy volunteers and 25 weeks for those with Alzheimers Disease.

Age: 18Years - 85YearsAll GendersPhase 1
18 locations
E

Actively Recruiting

Researchers are studying risankizumab, a drug approved for adults with certain conditions, to evaluate its effects in children aged 2 to under 18 years with moderately to severely active Crohns Disease who have not responded well or are intolerant to other treatments. This Phase 3 study includes three groups by age and involves multiple study parts to assess how the drug moves through the body, its safety, and its impact on disease activity. Participants will receive risankizumab through an intravenous infusion during a 12-week induction phase. Those who complete this phase may enter a 52-week maintenance period where they receive one of two doses of the drug by subcutaneous injection without knowing which dose they get. Afterward, participants can join a 208-week open-label extension phase with risankizumab dosing based on their previous response. During the study, participants will attend regular visits at hospitals or clinics where medical assessments, blood tests, and questionnaires will be used to monitor disease activity and check for side effects. Key measures include clinical remission and endoscopic response at 12 and 64 weeks. Follow-up continues for about 140 days after treatment periods, allowing researchers to understand the drugs effects and safety over time.

Age: 2Years - 17YearsAll GendersPhase 3
85 locations

1-10 of 17

1